We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-13.88%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$38.4M
AUM Growth
-$27.8M
(-42%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-56.13%
Top 10 Holdings %
Top 10 Hldgs %
85.77%
Holding
21
New
4
Increased
5
Reduced
7
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$4.95M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$1.58M |
| 3 |
XNPT
XENOPORT, INC.
XNPT
|
+$1.53M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$980K |
| 5 |
Neurocrine Biosciences
NBIX
|
+$885K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$7.68M |
| 2 |
ACOR
Acorda Therapeutics
ACOR
|
+$6.22M |
| 3 |
Centene
CNC
|
+$4.44M |
| 4 |
Edwards Lifesciences
EW
|
+$2.6M |
| 5 |
Alkermes
ALKS
|
+$2.33M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 69.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XNPT
1
DELISTED
XENOPORT, INC.
XNPT
| $7.34M | 19.13% |
1,627,628
+331,850
| +26% | +$1.53M |
|
|
2
Eli Lilly
LLY
$1.05T
| $4.71M | 12.28% |
+65,400
| New | +$4.95M |
|
3
Quest Diagnostics
DGX
$23.3B
| $4.54M | 11.85% |
63,595
-29,850
| -32% | -$2M |
|
|
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
| $2.82M | 7.35% |
333,513
+138,307
| +71% | +$980K |
|
|
NVRO
5
DELISTED
NEVRO CORP.
NVRO
| $2.78M | 7.24% |
49,377
-5,550
| -10% | -$327K |
|
|
6
Neurocrine Biosciences
NBIX
$17.2B
| $2.5M | 6.51% |
63,188
+22,300
| +55% | +$885K |
|
7
UnitedHealth
UNH
$387B
| $2.31M | 6.01% |
17,900
-17,786
| -50% | -$2.1M |
|
8
Teva Pharmaceuticals
TEVA
$37.3B
| $2.21M | 5.76% |
41,286
-34,000
| -45% | -$1.99M |
|
|
IPXL
9
DELISTED
Impax Laboratories, Inc.
IPXL
| $1.99M | 5.18% |
62,050
+10,620
| +21% | +$373K |
|
|
AERI
10
DELISTED
Aerie Pharmaceuticals
AERI
| $1.71M | 4.46% |
140,587
+54,692
| +64% | +$865K |
|
|
11
Bio-Rad Laboratories Class A
BIO
$8.15B
| $1.65M | 4.29% |
+12,050
| New | +$1.58M |
|
|
12
Edwards Lifesciences
EW
$49.4B
| $1.39M | 3.63% |
47,340
-94,350
| -67% | -$2.6M |
|
|
13
Centene
CNC
$32.8B
| $730K | 1.9% |
23,700
-148,578
| -86% | -$4.44M |
|
14
QuidelOrtho
QDEL
$1.19B
| $717K | 1.87% |
+41,550
| New | +$695K |
|
15
OraSure Technologies
OSUR
$266M
| $500K | 1.3% |
+69,200
| New | +$440K |
|
|
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $473K | 1.23% |
8,850
-6,741
| -43% | -$498K |
|
|
17
Alkermes
ALKS
$8.79B
| – | – |
-29,350
| Closed | -$2.33M |
|
18
Pacific Biosciences
PACB
$447M
| – | – |
-145,306
| Closed | -$1.91M |
|
|
19
PTC Therapeutics
PTCT
$6.52B
| – | – |
-237,100
| Closed | -$7.68M |
|
|
ACOR
20
DELISTED
Acorda Therapeutics
ACOR
| – | – |
-1,213
| Closed | -$6.22M |
|
|
SGYP
21
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| – | – |
-303,157
| Closed | -$1.72M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, Asymmetry Capital Management held 21 positions worth $38.4M, down 42% from $66.1M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Asymmetry Capital Management withdrew a net $21.5M in Q1 2016, closing 5 positions and reducing 7 holdings. Its most notable exit was PTC Therapeutics, an estimated $7.68M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 80% a quarter earlier.
Against the trend, Asymmetry Capital Management opened a new position in Eli Lilly worth $4.71M.
- Asymmetry Capital Management's largest Q1 2016 buy was Eli Lilly: 65,400 shares worth $4.71M.
- Asymmetry Capital Management added most to XENOPORT, INC. in Q1 2016, an estimated $1.53M increase.
- Asymmetry Capital Management's biggest Q1 2016 reduction was Centene, cutting an estimated $4.44M.
- Asymmetry Capital Management fully exited PTC Therapeutics in Q1 2016, selling an estimated $7.68M.
- Asymmetry Capital Management's ten largest holdings make up 86% of its $38.4M portfolio in Q1 2016.
- Asymmetry Capital Management opened 4 new positions and closed 5 in Q1 2016.
- Asymmetry Capital Management's portfolio value fell 42% quarter-over-quarter to $38.4M.
Based on Asymmetry Capital Management's 13F filing for Q1 2016, filed 21 Apr 2016.